ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
13 mai 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, May 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering
12 mai 2022 08h30 HE
|
ABVC BioPharma, Inc.
Fremont, CA, May 12, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it has entered into securities purchase...
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
10 mai 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, May 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process
05 mai 2022 08h30 HE
|
ABVC BioPharma, Inc.
New Process Improves Quality and Lowers Cost Fremont, CA, May 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company...
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed
03 mai 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, May 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
28 avr. 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, April 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
26 avr. 2022 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, April 26, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
31 mars 2022 16h18 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that seeks to deliver...
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
23 mars 2022 09h25 HE
|
ABVC BioPharma, Inc.
Fremont, CA, March 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
02 févr. 2022 08h00 HE
|
ABVC BioPharma, Inc.
Fremont, CA, Feb. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...